• Text Size
  • Print
  • Share

I talk

I'm Auvi‑Q, a breakthrough in epinephrine auto‑injector (EAI) design, for patients at risk for life‑threatening allergic reactions.

Learn More About Auvi‑Q

What Do Survey
Participants
Think Of

Auvi‑Q?

Learn more about
the results from a
comparative survey.

Primary
Survey
Objectives:

-Size

-Shape

-Method of
-Instruction

I Have

Audio &

Visual Cues

Auvi‑Q guides patients through the injection process step by step.

Did You

Know?

In a large survey, 71% of caregivers of at-risk children (n=405) responded that they do not always carry their epinephrine auto‑injectors (EAIs).1*

Always Carry 29%
Do Not Always Carry 71%
*Participants must have filled a prescription for
an EAI in the previous 36 months.

Tools

& Support

Access resources for you, your patients and their caregivers, including training materials and allergy ID cards.

Designed to be3:
Easy to Carry
Easy to Use

And now

Easy to Prescribe

Hear my voice instructions:

Indication

Auvi‑Q® (epinephrine injection, USP) is indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to allergens, idiopathic and exercise-induced anaphylaxis. Auvi‑Q is intended for individuals with a history of anaphylaxis or who are at risk for anaphylactic reactions.

Important Safety Information

Auvi‑Q should ONLY be injected into the anterolateral aspect of the thigh. DO NOT INJECT INTO BUTTOCK OR INTRAVENOUSLY.

Epinephrine should be administered with caution to patients with certain heart diseases, and in patients who are on medications that may sensitize the heart to arrhythmias, because it may precipitate or aggravate angina pectoris and produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported in patients with underlying cardiac disease or taking cardiac glycosides or diuretics. Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions. Adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties.

Auvi‑Q is intended for immediate self-administration as emergency supportive therapy only and is not a substitute for immediate medical or hospital care.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.

Please see full Prescribing Information.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

References

  1. Data on file. July 2011. EAI Consumer Buying Process. sanofi-aventis Pharmaceuticals Inc.
  2. Auvi‑Q [prescribing information]. sanofi‑aventis U.S., LLC: Bridgewater, NJ.
  3. Edwards ES, Edwards ET, Gunn R, Patterson P, North R. Design validation and labeling comprehension study for a new epinephrine. Ann Allergy Asthma Immunol. 2013;110:189-193.e1.

References | Site Map | FAQs

© 2015 sanofi-aventis U.S. LLC, A SANOFI COMPANY.
Legal Disclaimer and Privacy Policy
Questions or Comments? Click here to contact us.
This site is intended for use by U.S. Healthcare Professionals only.
US.EAI.14.10.003 Last Update: December 2014

You Are About to Leave a Sanofi US Web Site

Please note:

By clicking on this link, you will be leaving this Sanofi US Web site and going to another, entirely independent, Web site. Sanofi US provides these links as a service to its Web site visitors and users; however, it takes no responsibility for the information on any Web site but its own.

Click the "Continue" button below to go to the page you requested or click "Cancel" to remain on the page.

Cancel